URGN PEER ANALYSIS

UroGen Pharma Ltd — metric-by-metric comparison with peers and the industry median

URGNUroGen Pharma Ltd

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

URGNIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	URGN	TLX	MSB	CSL	RTALB	Ind. Median
P/E	—	—	—	29.44	4.89●	17.91
P/B	-15.36●	6.37	—	2.20	0.61	3.51
EV/EBITDA	—	120.14	—	10.21●	74.61	14.82
P/S	13.58	3.24	31.61	2.62●	6.67	10.89

Financial Health
Metric	URGN	TLX	MSB	CSL	RTALB	Ind. Median
Current Ratio	4.69●	1.43	—	2.57	1.21	5.90
Debt/Equity	-158.6%●	112.3%	—	67.4%	1.2%	10.9%
NetDebt/EBITDA	-0.48●	13.13	—	2.22	0.90	1.15

Profitability
Metric	URGN	TLX	MSB	CSL	RTALB	Ind. Median
Net Margin	-94.8%	-0.9%	-115.3%	9.2%	136.3%●	-125.7%
ROE	—	-1.8%	-11.3%	7.7%	15.1%●	-47.5%
ROA	-53.2%	-0.7%	-8.6%	3.8%	13.1%●	-35.8%
EBITDA Margin	-82.4%	3.0%	-76.6%	32.8%●	9.0%	-105.8%

Growth + Dividend
Metric	URGN	TLX	MSB	CSL	RTALB	Ind. Median
Rev. Growth	52.9%	56.3%	410.4%●	4.8%	24.0%	5.1%
NI Growth	—	—	—	-39.4%	134.0%●	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.0%	0.2%
Payout	—	—	0.0%	103.1%	0.0%	0.0%

Valuation
Metric	URGN	INVA	TYRA	SNDX	ZYME	VRDN	Ind. Median
P/E	—	3.75	—	—	—	—	17.91
P/B	-15.36●	1.41	4.88	45.41	12.01	3.12	3.51
EV/EBITDA	—	2.52	—	—	—	—	14.82
P/S	13.58	4.46●	—	8.70	24.18	27.96	10.89

Financial Health
Metric	URGN	INVA	TYRA	SNDX	ZYME	VRDN	Ind. Median
Current Ratio	4.69	21.13●	20.49	5.47	10.82	15.15	5.90
Debt/Equity	-158.6%●	24.7%	1.5%	829.8%	10.4%	8.0%	10.9%
NetDebt/EBITDA	-0.48●	-0.44	2.89	0.04	3.69	2.03	1.15

Profitability
Metric	URGN	INVA	TYRA	SNDX	ZYME	VRDN	Ind. Median
Net Margin	-94.8%	118.9%●	—	-112.0%	-126.3%	-508.5%	-125.7%
ROE	—	50.7%●	-36.9%	-189.5%	-42.0%	-58.1%	-47.5%
ROA	-53.2%	32.6%●	-34.7%	-43.7%	-22.7%	-49.7%	-35.8%
EBITDA Margin	-82.4%	150.9%●	—	-74.8%	-116.1%	-492.7%	-105.8%

Growth + Dividend
Metric	URGN	INVA	TYRA	SNDX	ZYME	VRDN	Ind. Median
Rev. Growth	52.9%	13.6%	-100.0%	396.7%	-13.0%	23,382.8%●	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on URGN

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.